3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
11
Stomach Neoplasms
6
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Salivary Gland Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
5
Nivolumab
5
selpercatinib
4
Iodine-124
4
Biopsy
4
pembrolizumab
3
binimetinib
3
Iodine-131
3
Cetuximab
3
ulixertinib
2
trametinib
2
omipalisib
2
lenvatinib
2
larotrectinib
2
durvalumab
2
defactinib
2
dabrafenib
2
Surveys and Questionnaires
2
Sunitinib
2
Radiosurgery
2
Ipilimumab
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
tremelimumab
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
trastuzumab deruxtecan
×
90 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled